Eleventh Circuit Upholds Whistleblower Suits in Florida Medicare Fraud Case

The U.S. Court of Appeals for the Eleventh Circuit has vacated a Florida district court ruling that had declared the False Claims Act's whistleblower provisions unconstitutional, reviving a Medicare Advantage fraud case against a Florida health care network and preserving a fraud enforcement tool the federal government has relied on since the Civil War. The unanimous three-judge panel issued its decision on September 1 in United States ex rel. Zafirov v. Florida Medical Associates LLC.

What the case is about

The underlying lawsuit was brought by Dr. Clarissa Zafirov, a board-certified family care physician, against her former employer, which does business as VIPcare. Zafirov alleged that the network systematically submitted false diagnosis codes to Medicare Advantage in order to inflate the monthly risk-adjustment payments it received.

Medicare Advantage pays private plans a fixed monthly amount per enrollee, adjusted upward for patients with more serious documented conditions. That structure creates an incentive to document diagnoses aggressively, and risk-adjustment coding has become one of the most active areas of federal health care fraud enforcement nationally.

Zafirov brought her claim as a relator under the False Claims Act's qui tam provisions, which allow a private citizen with knowledge of fraud against the government to file suit on the government's behalf. The government may intervene and take over the case, or decline and let the relator proceed. A successful relator receives a share of any recovery.

The constitutional ruling that was vacated

In 2024, U.S. District Judge Kathryn Kimball Mizelle, sitting in the Middle District of Florida, dismissed the case on constitutional grounds. She held that the qui tam mechanism improperly allows a private citizen to wield executive branch authority, and that a relator prosecuting a case on the government's behalf functions as an officer of the United States who has not been appointed in the manner the Appointments Clause of Article II requires.

The ruling was a significant departure. Qui tam suits have been part of American law since the founding era, and the modern False Claims Act's whistleblower provisions have been in place in their current form since 1986 amendments that substantially strengthened them. The decision drew immediate national attention because, if upheld and extended, it would have eliminated the mechanism that generates a large share of federal fraud recoveries.

The Eleventh Circuit disagreed. The panel rejected the Appointments Clause challenge, holding that private relators who sue on behalf of the United States are not acting as improperly appointed federal officers. The decision vacates the dismissal and sends the case back to the district court.

What the panel left open

The ruling was not a complete constitutional endorsement. The panel remanded for consideration of other constitutional challenges that the district court did not need to reach once it dismissed on Appointments Clause grounds.

The most significant of those is a challenge grounded in Article II's vesting of executive power and the president's removal authority. The argument is that even if a relator is not an officer requiring appointment, allowing a private party to control litigation on the government's behalf, without presidential supervision or removal power, impermissibly intrudes on executive authority.

Legal commentators reviewing the decision have noted that the Article II questions remain genuinely open and that the litigation is likely to continue. Several have raised the possibility of eventual Supreme Court review, particularly if other circuits reach different conclusions.

Why this matters beyond Florida

The False Claims Act is the federal government's primary civil fraud statute, and the qui tam mechanism generates the majority of the cases brought under it. Recoveries under the act have run into the billions of dollars annually in recent years, with health care fraud consistently the largest category, followed by defense procurement.

The mechanism exists because the government cannot detect most fraud on its own. Fraudulent billing is visible primarily to people inside the organization doing it, and the qui tam structure creates a financial incentive for those people to come forward while providing legal protection against retaliation.

Had the district court's reasoning been affirmed and extended nationally, the practical consequence would have been the elimination of most federal fraud enforcement capacity in health care. The Eleventh Circuit's ruling prevents that outcome for now, in a circuit covering Florida, Georgia and Alabama.

The Florida stakes

Florida is among the most consequential jurisdictions in the country for health care fraud enforcement. The state has a large Medicare-eligible population, an enormous Medicare Advantage enrollment, a dense concentration of home health, durable medical equipment, hospice and pharmacy operators, and a long enforcement history that includes the U.S. Attorney's offices in the Southern and Middle Districts working some of the largest health care fraud prosecutions in the country.

Medicare Advantage penetration in Florida is among the highest of any state, which makes risk-adjustment coding practices a matter of direct fiscal consequence to the federal program and, indirectly, to the beneficiaries whose plan options and premiums are shaped by it.

For Florida health care employers, the ruling restores the pre-2024 legal environment. Compliance programs, internal reporting channels and coding audits remain the operative risk management tools, and the exposure created by a former employee with documentation has not diminished.

What it means for Floridians

For patients, the connection is indirect but real. Medicare Advantage overpayment driven by inflated diagnosis coding raises federal program costs without improving care, and it can distort clinical documentation in ways that follow a patient through their records.

For health care workers in Florida, the decision preserves a legal avenue. Employees who observe billing practices they believe are fraudulent retain the ability to bring a qui tam action, and the act's anti-retaliation provisions remain available to those who report internally or externally.

For taxpayers, the practical effect is the continued operation of the enforcement mechanism that recovers the largest share of federal fraud losses. Whether that mechanism survives the Article II challenges still pending is a question the courts have not answered.

How the case proceeds

The matter returns to the Middle District of Florida for consideration of the remaining constitutional arguments. If the district court rejects them, the case would move toward the merits of Zafirov's underlying allegations, which have never been adjudicated. The defendants have not been found liable of anything, and the constitutional litigation has consumed the case to this point without reaching the factual claims.

Appeals are likely regardless of the outcome on remand. The constitutional questions are significant enough, and the stakes for federal enforcement large enough, that both sides have incentive to pursue every available level of review.

How qui tam cases actually work

A relator files the complaint under seal in federal district court, meaning it is not public and the defendant is not notified. The complaint is served on the government along with a written disclosure of substantially all material evidence the relator possesses.

The Department of Justice then investigates, typically over a period measured in years rather than months, with the seal extended repeatedly by court order. During that period the defendant may have no knowledge the case exists.

At the conclusion of its investigation the government elects whether to intervene. Intervention means the government takes primary responsibility for prosecuting the action, and intervened cases historically recover far more than declined ones. If the government declines, the relator may proceed alone, bearing the litigation cost.

Recovery is shared. A relator in an intervened case generally receives between 15 and 25 percent of the proceeds. In a declined case where the relator prosecutes successfully, the share rises to between 25 and 30 percent. Damages under the act are trebled, and per-claim civil penalties apply, which is why judgments and settlements can reach very large figures.

Medicare Advantage and risk adjustment

The specific fraud theory in this case turns on a payment mechanism that most patients never see. Medicare Advantage plans receive a capitated monthly payment per enrollee rather than fee-for-service reimbursement, and that payment is adjusted based on the enrollee's documented health conditions.

The adjustment exists for a defensible reason. Without it, plans would have a powerful incentive to enroll only healthy members and avoid sick ones. Risk adjustment neutralizes that incentive by paying more for members who cost more to care for.

The vulnerability is that the payment depends on documentation rather than on treatment. A diagnosis code entered in a record increases payment whether or not the condition is treated, and whether or not it is accurately supported by the clinical record.

Federal enforcement has focused on several recurring patterns: in-home assessments conducted primarily to generate diagnosis codes, retrospective chart reviews that add codes without deleting unsupported ones, and provider compensation arrangements that reward coding intensity. Whether any of that occurred in this case is what the litigation will now proceed to examine.

Florida's high Medicare Advantage enrollment means the state sits at the center of this enforcement area, and cases originating in Florida federal courts have shaped national doctrine repeatedly.

Florida health systems and physician groups have generally responded to the enforcement environment by investing in compliance infrastructure, including internal audit programs that sample coded diagnoses against the underlying clinical documentation. Those programs are also the mechanism through which employees most often first raise concerns, which means the quality of an organization's internal reporting channel frequently determines whether an issue is resolved internally or arrives as a federal complaint years later.

What's next

Watch for the district court's handling of the remanded Article II questions and for how other circuits address similar challenges. A circuit split would substantially raise the odds of Supreme Court review.

Health care compliance officers in Florida are likely to treat the ruling as a return to normal risk assumptions rather than as a change. The exposure that existed before 2024 exists now, and the brief window in which some defendants argued the entire mechanism was unconstitutional has closed, at least in this circuit and at least for the moment.